Higher METTL3 expression levels are significantly associated with poor overall survival in ACC, KICH, and LIHC and poorer DFS in ACC, CESC, HNSC, KICH, and LIHC, supporting the potential of METTL3 as a prognostic biomarker in cancers, particularly in ACC, KICH, and LIHC. The gene discussed is METTL3; the disease is cancer.